Protalix BioTherapeutics, Inc.
Christian Elze (Director) reports PLX insider transactions
About this filing
Protalix BioTherapeutics, Inc. (PLX) filed Form 4 (insider transaction) with the SEC on Sep 4, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Christian Elze · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | A · grantStock Options (Right to Buy)Footnotes F1, F2 | +17,000 | $0.00 | $0.00 | 17,000 | Direct |
| Sep 3, 2026 | A · grantRestricted Stock UnitsFootnotes F3, F4 | +8,500 | $0.00 | $0.00 | 8,500 | Direct |
Footnotes
- F1 The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
- F2 Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
- F3 Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
- F4 The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
More PLX filings
- SC 13G
Filed Oct 15, 2026
- 4
Filed Sep 9, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.